You searched for rivaroxaban - Page 2 of 15 - MPR

Your search for rivaroxaban returned 143 results

Your search for rivaroxaban returned 143 results

Sort Results:

Relevant Recent
American College of Cardiology 2011

Rivaroxaban Compares Favorably With Enoxaparin for VTE Prevention in Acute Conditions But Demonstrates No Net Clinical Benefit

Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but demonstrates weaker safety outcomes, according to results of the MAGELLAN trial presented today at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
News

Benefits of Rivaroxaban, Aspirin Compared After Hip, Knee Arthroplasty

The researchers found that venous thromboembolism occurred in 0.64 and 0.7% of patients in the aspirin and rivaroxaban groups, respectively (difference, 0.06 percentage points; 95% confidence interval [CI], −0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority).
News

Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE

Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…